



Calithera Announces Multiple Abstracts Selected for Presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 26, 2015

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer agents, today announced that two abstracts have been selected for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 5-9, 2015 in Boston, Massachusetts. Details for the presentations are as follows:

CB-1158 Inhibits the Immuno-oncology Target Arginase, and Causes an Immune Mediated Anti-Tumor Response

Abstract #A195

Matthew Gross, Calithera Biosciences

Poster Session A, Tumor Immunology Targets

Friday, November 6, 2015 at 12:15-3:15 PM EST

Hynes Convention Center, Exhibit Hall C-D

Phase I study of CB-839, a First-in-class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Refractory Solid Tumors

Abstract #C49

Funda Meric-Bernstam, M.D., MD Anderson Cancer Center

Poster Session C, Clinical Trials

Sunday, November 8, 2015 at 12:30-3:30 PM EST

Hynes Convention Center, Exhibit Hall C-D

The meeting abstracts can be viewed online through the AACR website at www.AACR.org.

About Calithera Biosciences

Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.

CONTACT: Jennifer McNealey

ir@Calithera.com

650-870-1071



Calithera Biosciences, Inc.